title: The HepCar registry: report on a one-year registration program of hepatocellular carcinoma (HCC) in Belgium. What is daily practice in HCC?
abstract: BACKGROUND
  Due to a rise in HCV induced liver cirrhosis, hepatocellular carcinoma becomes more prevalent in Western European countries. The HepCar registry is an initiative in which patients with hepatocellular carcinoma, their treatment and follow up are registered.
  
  
  METHODS
  Belgian physicians were asked to report all new cases of hepatocellular carcinoma which were seen between January 2003 and December 2003. Reporting was done on a voluntary basis. Data reported were: demographic figures, the nature of the underlying liver disease, presentation characteristics of the tumour, laboratory findings and choice of therapy. Every six months, a reminder was sent to determine survival.
  
  
  RESULTS
  131 patients (94 male/37 female) were reported. Mean age was 63 years +/- 13. Underlying liver disease was HCV (n = 54, 41%), HBV (n = 22, 17%), alcoholic liver disease (n = 39, 30%) and miscellaneous (n =16, 12%). Diagnosis of hepatocellular carcinoma was made by surveillance in 47 (36%) patients. After logistic regression, survival was 5 times better for patients inside the Milan criteria (one lesion less than 5 cm in diameter or less than 3 nodules each less than 3 cm in the absence of vascular invasion and metastasis).
  
  
  CONCLUSIONS
  Tumours inside the Milan criteria have a better survival. The majority of the patients have an underlying cirrhosis as background for the development of a HCC.
authors.affiliation: Department of Gastroenterology and Hepatology, Ghent University Hospital, Belgium. hans.vanvlierberghe@ugent.be
authors.forename: H
authors.initials: H
authors.lastname: Van Vlierberghe
authors.forename: I
authors.initials: I
authors.lastname: Colle
authors.forename: J
authors.initials: J
authors.lastname: Henrion
authors.forename: P
authors.initials: P
authors.lastname: Michielsen
authors.forename: J
authors.initials: J
authors.lastname: Delwaide
authors.forename: H
authors.initials: H
authors.lastname: Reynaert
authors.forename: I
authors.initials: I
authors.lastname: Borbath
authors.forename: J P
authors.initials: JP
authors.lastname: Martinet
authors.forename: D
authors.initials: D
authors.lastname: Sprengers
authors.forename: R
authors.initials: R
authors.lastname: Brenard
mesh_terms: D017677:Age Distribution; D000368:Aged; D001530:Belgium / Q000453:epidemiology; D001707:Biopsy, Needle; D006528:Carcinoma, Hepatocellular / Q000175:diagnosis* / Q000453:epidemiology* / Q000628:therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000453:epidemiology* / Q000628:therapy; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D015995:Prevalence; D011446:Prospective Studies; D012042:Registries; D018570:Risk Assessment; D017678:Sex Distribution; D015996:Survival Rate